MX2019010732A - Uso de moduladores de receptor de glucocorticoide en el tratamiento de tumores secretores de catecolamina. - Google Patents

Uso de moduladores de receptor de glucocorticoide en el tratamiento de tumores secretores de catecolamina.

Info

Publication number
MX2019010732A
MX2019010732A MX2019010732A MX2019010732A MX2019010732A MX 2019010732 A MX2019010732 A MX 2019010732A MX 2019010732 A MX2019010732 A MX 2019010732A MX 2019010732 A MX2019010732 A MX 2019010732A MX 2019010732 A MX2019010732 A MX 2019010732A
Authority
MX
Mexico
Prior art keywords
catecholamine
cst
syndrome
bind
tumors
Prior art date
Application number
MX2019010732A
Other languages
English (en)
Spanish (es)
Inventor
G Moraitis Andreas
Original Assignee
Corcept Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Corcept Therapeutics Inc filed Critical Corcept Therapeutics Inc
Publication of MX2019010732A publication Critical patent/MX2019010732A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
MX2019010732A 2017-03-09 2018-03-08 Uso de moduladores de receptor de glucocorticoide en el tratamiento de tumores secretores de catecolamina. MX2019010732A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762469296P 2017-03-09 2017-03-09
PCT/US2018/021592 WO2018165460A1 (en) 2017-03-09 2018-03-08 Use of glucocorticoid receptor modulators in the treatment of catecholamine-secreting tumors

Publications (1)

Publication Number Publication Date
MX2019010732A true MX2019010732A (es) 2019-11-01

Family

ID=63446773

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019010732A MX2019010732A (es) 2017-03-09 2018-03-08 Uso de moduladores de receptor de glucocorticoide en el tratamiento de tumores secretores de catecolamina.

Country Status (8)

Country Link
US (1) US11045482B2 (cg-RX-API-DMAC7.html)
EP (1) EP3592358A4 (cg-RX-API-DMAC7.html)
JP (4) JP7564620B2 (cg-RX-API-DMAC7.html)
CN (1) CN110475558A (cg-RX-API-DMAC7.html)
AU (1) AU2018230429B2 (cg-RX-API-DMAC7.html)
CA (1) CA3053806A1 (cg-RX-API-DMAC7.html)
MX (1) MX2019010732A (cg-RX-API-DMAC7.html)
WO (1) WO2018165460A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2021007402A (es) 2018-12-20 2021-07-15 Corcept Therapeutics Inc Metodos para la toma de imagenes y el tratamiento de tumores positivos para el receptor de somatostatina.
JP2021079146A (ja) * 2021-02-22 2021-05-27 株式会社三洋物産 遊技機
JP7315071B2 (ja) * 2021-03-03 2023-07-26 株式会社三洋物産 遊技機

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9606736D0 (en) 1996-02-19 1996-06-05 Shire International Licensing Therapeutic method
CA2246791A1 (en) 1998-09-01 2000-03-01 Alison Buchan Treatment of endothelium with somatostatin analogues
US6818739B2 (en) 1999-12-03 2004-11-16 Ndsu Research Foundation Somatostatins
US6139845A (en) 1999-12-07 2000-10-31 Allergan Sales, Inc. Method for treating cancer with a neurotoxin
JP2004525135A (ja) 2001-03-23 2004-08-19 コーセプト セラピューティクス, インコーポレイテッド 糖質コルチコイドレセプター特異的アンタゴニストを使用するストレス障害を処置するための方法
WO2003057214A1 (en) 2001-12-28 2003-07-17 Somatocor Pharmaceuticals, Inc. Imidazolidin-2,4-dione derivatives as non-peptide somatostatin receptor ligands
RU28362U1 (ru) 2002-12-10 2003-03-20 Закрытое акционерное общество "Дальневосточная технология" Лист заходной футеровки
JP4931794B2 (ja) 2004-03-09 2012-05-16 コーセプト セラピューティクス, インコーポレイテッド 縮合環アザデカリン糖質コルチコイド受容体モジュレーター
GB0428151D0 (en) * 2004-12-22 2005-01-26 Novartis Ag Organic compounds
EP2145186A4 (en) * 2007-05-15 2010-10-20 Water Technologies Corp DEVICE AND METHOD FOR THE DETECTION OF METANEPHRINES IN PLASMA
EP2532350A1 (en) 2007-10-17 2012-12-12 Laboratoire HRA Pharma Pharmaceutical combination of a glucocorticoid receptor antagonist and a cortisol synthesis inhibitor for treating cushing's syndrome
ES2351569B8 (es) 2009-05-07 2012-06-20 Bcn Peptides S.A. Ligandos peptídicos de receptores de somatostatina.
AU2010247766B2 (en) 2009-05-12 2015-05-21 Corcept Therapeutics, Inc. Solid forms and process for preparing
WO2011094814A1 (en) * 2010-02-05 2011-08-11 Phosphagenics Limited Carrier comprising non-neutralised tocopheryl phosphate
CN103596431B (zh) 2011-03-18 2016-06-22 科赛普特治疗公司 嘧啶环己基糖皮质激素受体调节剂
WO2013039916A1 (en) * 2011-09-12 2013-03-21 The United States Of America, Represented By The Secretary, Dept. Of Health And Human Services Compositions for and methods of treatment and enhanced detection of non-pituitary tumors
US8859774B2 (en) 2012-05-25 2014-10-14 Corcept Therapeutics, Inc. Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
ES2943542T3 (es) 2013-11-25 2023-06-14 Corcept Therapeutics Inc Moduladores del receptor de glucocorticoides de azadecalina condensada con octahidro
JP6821582B2 (ja) * 2015-03-02 2021-01-27 コーセプト セラピューティクス, インコーポレイテッド Acth分泌腫瘍を処置するための糖質コルチコイドレセプターアンタゴニストおよびソマトスタチンアナログの使用
US9943526B2 (en) * 2015-04-21 2018-04-17 Corcept Therapeutics, Inc. Optimizing mifepristone levels for cushing's patients

Also Published As

Publication number Publication date
CN110475558A (zh) 2019-11-19
US20180256604A1 (en) 2018-09-13
CA3053806A1 (en) 2018-09-13
JP7564620B2 (ja) 2024-10-09
JP2024074854A (ja) 2024-05-31
WO2018165460A1 (en) 2018-09-13
EP3592358A1 (en) 2020-01-15
JP2020510011A (ja) 2020-04-02
EP3592358A4 (en) 2020-12-16
US11045482B2 (en) 2021-06-29
AU2018230429B2 (en) 2023-06-15
JP2022090003A (ja) 2022-06-16
JP2026099911A (ja) 2026-06-18
AU2018230429A1 (en) 2019-09-05

Similar Documents

Publication Publication Date Title
MX2009011540A (es) Tratamiento de desordenes de movimiento con el uso combinado de toxina botulinica y estimulacion del musculo.
ZA202006481B (en) Anti-msr1 antibodies and methods of use thereof
MX2019009227A (es) Métodos para tratar cáncer con inhibidores de hsp90.
SG10201902664RA (en) Combination therapy for treating cancer
EA201890146A1 (ru) СПОСОБЫ ЛЕЧЕНИЯ СОЛИДНЫХ ОПУХОЛЕЙ С ИСПОЛЬЗОВАНИЕМ КОМБИНИРОВАННОЙ ТЕРАПИИ ИНГИБИТОРОМ mTOR В ВИДЕ НАНОЧАСТИЦ
MX387885B (es) Inhibidores de ezh2 para tratar linfomas.
MX2019013279A (es) Metodos de tratamiento del sindrome de doose utilizando fenfluramina.
MX2020008680A (es) Terapia de combinacion con apilimod y agentes glutamatergicos.
EA201650134A1 (ru) Специфическая сочетанная терапия злокачественных опухолей цитостатиком и его модификатором
MY199903A (en) Combination therapy with controlled-release cnp agonists
MX2018001435A (es) Metodos de tratamiento del sindrome de lennox-gastaut con fenfluramina.
GB2454118A (en) Hdac inhibitors and hormone targeted drugs for the treatment of cancer
EA200900203A1 (ru) Избирательные модуляторы рецептора андрогенов, их аналоги, производные и применение
EA201590144A1 (ru) Rspo3-связывающие агенты и их применение
PL2288413T3 (pl) Urządzenie terapeutyczne łączące radioterapię z termoterapią
PH12022551021A1 (en) Sequential anti-cd19 therapy
MX2017006938A (es) Terapia de combinacion para el tratamiento de cancer.
MX2018010223A (es) Terapia combinada para tratamiento de cancer de ovario.
ZA202304965B (en) Combination therapy for treating cancer
EA201792294A1 (ru) Комбинированное лечение (варианты) с применением серибантумаба
MX2020004960A (es) Asociacion de activos para tratar el cancer de prostata.
EA201592058A1 (ru) Применение ландиолола гидрохлорида в длительном лечении тахиаритмии
JOP20200124A1 (ar) طُرق لعلاج سرطان المثانة باستخدام جيمسيتابين وعلاج مدوامة لذلك
WO2019118779A3 (en) Peptides and other agents for treating pain and increasing pain sensitivity
MX2021007402A (es) Metodos para la toma de imagenes y el tratamiento de tumores positivos para el receptor de somatostatina.